Allena Pharmaceuticals, Inc.·4

Nov 6, 6:46 PM ET

FHM VI, L.P. 4

4 · Allena Pharmaceuticals, Inc. · Filed Nov 6, 2017

Insider Transaction Report

Form 4
Period: 2017-11-06
Transactions
  • Conversion

    Common Stock

    2017-11-06+2,830,3732,830,373 total(indirect: By Frazier Healthcare VI, L.P.)
  • Purchase

    Common Stock

    2017-11-06$14.00/sh+500,000$7,000,0003,330,373 total(indirect: By Frazier Healthcare VI, L.P.)
  • Conversion

    Series A Preferred Stock

    2017-11-066,122,4480 total(indirect: By Frazier Healthcare VI, L.P.)
    Common Stock (1,466,805 underlying)
  • Conversion

    Series B Preferred Stock

    2017-11-064,629,6300 total(indirect: By Frazier Healthcare VI, L.P.)
    Common Stock (1,109,159 underlying)
  • Conversion

    Series C Preferred Stock

    2017-11-061,061,9040 total(indirect: By Frazier Healthcare VI, L.P.)
    Common Stock (254,409 underlying)
Footnotes (5)
  • [F1]The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer.
  • [F2]The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer.
  • [F3]The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer.
  • [F4]The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.
  • [F5]Not applicable.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION